Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diagnostic Multicenter Phase II Study, Prospective, Comparative, of 68Ga-HBED-PSMA PET / CT and Conventional Imaging Procedures in Occult Biological Relapse Prostate Cancer

Next Previous
Trial Profile

Diagnostic Multicenter Phase II Study, Prospective, Comparative, of 68Ga-HBED-PSMA PET / CT and Conventional Imaging Procedures in Occult Biological Relapse Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Acronyms PSMA REBIOLOC

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 May 2018 Planned End Date changed from 29 Sep 2018 to 29 Sep 2019.
    • 29 May 2018 Planned primary completion date changed from 15 Apr 2018 to 31 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top